HBM Biopharma Summit 2023

September 24, 2023 - September 26, 2023

Park Hyatt Zurich

About

Dear guests,

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum pharetra tempor felis sollicitudin pharetra. Sed pulvinar viverra massa nec ullamcorper. Vestibulum aliquet eget magna nec faucibus. Pellentesque placerat eleifend lorem. Aliquam at ligula ut elit dapibus congue. Cras sit amet purus tellus. Integer sodales nisl a ligula blandit, sed venenatis nunc gravida. Duis orci augue, iaculis quis semper et, dignissim vel odio. Aliquam dapibus vel lectus a luctus. Quisque in arcu quis felis pellentesque vehicula et sit amet sem. Nulla at tempus nunc. Integer diam sem, tincidunt eu nibh in, volutpat scelerisque elit. Morbi neque nulla, fermentum eget tortor vel, consequat porttitor massa. Sed tincidunt, nunc eu interdum pellentesque, orci tortor elementum odio, ut consequat mauris nibh a ex. Mauris tincidunt nec diam sit amet tempor.

Schedule

Highlights

Speakers

Richard Girling
Partner, Centerview Partners

Richard Girling is one of Europe’s leading healthcare bankers with over 20 years of experience. Mr. Girling has advised on many of the largest healthcare transactions in Europe and Asia including: SanofiSynthelabo's $73 billion acquisition of Aventis, the $24 billion LBO of Alliance Boots plc, AstraZeneca in its $15 billion acquisition of MedImmune, Mayne Pharma's $2 billion sale to Hospira, Alliance Unichem in its $12 billion merger with Boots, CSL in its acquisition of Aventis Behring, and numerous transactions for Roche including the sale of its Vitamins division to DSM for $2 billion.

Since the creation of the Healthcare practice at Centerview Partners, the Healthcare team has advised on a number of significant transactions including: Alliance Boots on its formation of a strategic partnership with Walgreens and its sale in a two-step $27bn transaction, the $4 billion sale of OSI to Astellas, the $3 billion acquisition of the real estate assets of Atria Senior Living Group by Ventas, the $722 million sale of Facet Biotech to Abbott Labs, the $500 million acquisition of a 46% stake in Stallergenes by Ares Life Sciences and the $112 million acquisition of Baxter’s Multisource injectable pharma business and the $153 million acquisition of a 94.1% interest in Promopharm by Hikma. Mr. Girling established Merrill Lynch’s European healthcare practice in 1998, and was Global Co-Head of Healthcare investment banking for the last six of those years. Following the acquisition by Bank of America, he was appointed the head of the merged Europe, Middle East and Asia (EMEA) and Asia-Pacific healthcare practices for the combined organization. Mr. Girling joined Merrill Lynch in 1998 from Salomon Brothers, where he worked from 1989 to 1998 and was head of the European Pharmaceutical and Healthcare team. Mr. Girling is a member of the Development Board, St Anne's College, Oxford University and is actively involved in supporting oncology research projects with Imperial College Trust, London. Mr. Girling holds a B.A. and M.A. degrees in Biochemistry from Oxford University.

Location

Park Hyatt Zurich is perfectly situated between the picturesque Lake Zurich and the famous Old Town. Indulge in the finest elements of the Swiss commitment to serenity, luxury and art. Enjoy culinary delights, first-class service and all that Zurich has to offer, right from your doorstep.


Registration